HK1138326A1 - 利用包含不含質粒功能核酸的由菌群衍生的、完整的微細胞來作體內運送到哺乳動物細胞 - Google Patents

利用包含不含質粒功能核酸的由菌群衍生的、完整的微細胞來作體內運送到哺乳動物細胞

Info

Publication number
HK1138326A1
HK1138326A1 HK10105130.8A HK10105130A HK1138326A1 HK 1138326 A1 HK1138326 A1 HK 1138326A1 HK 10105130 A HK10105130 A HK 10105130A HK 1138326 A1 HK1138326 A1 HK 1138326A1
Authority
HK
Hong Kong
Prior art keywords
bacterially
derived
nucleic acid
mammalian cells
vivo delivery
Prior art date
Application number
HK10105130.8A
Other languages
English (en)
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Toby Hulf
Original Assignee
Engeneic Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd filed Critical Engeneic Molecular Delivery Pty Ltd
Publication of HK1138326A1 publication Critical patent/HK1138326A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11021—Polo kinase (2.7.11.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Manufacturing & Machinery (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HK10105130.8A 2007-03-30 2010-05-25 利用包含不含質粒功能核酸的由菌群衍生的、完整的微細胞來作體內運送到哺乳動物細胞 HK1138326A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90907407P 2007-03-30 2007-03-30
PCT/IB2008/002984 WO2009027830A2 (en) 2007-03-30 2008-03-26 Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells

Publications (1)

Publication Number Publication Date
HK1138326A1 true HK1138326A1 (zh) 2010-08-20

Family

ID=40386454

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10105130.8A HK1138326A1 (zh) 2007-03-30 2010-05-25 利用包含不含質粒功能核酸的由菌群衍生的、完整的微細胞來作體內運送到哺乳動物細胞
HK15110506.9A HK1209786A1 (zh) 2007-03-30 2015-10-26 包含調節性 的細菌衍生的完整微細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15110506.9A HK1209786A1 (zh) 2007-03-30 2015-10-26 包含調節性 的細菌衍生的完整微細胞

Country Status (18)

Country Link
EP (5) EP2865755B1 (zh)
JP (1) JP5167338B2 (zh)
CN (2) CN105854029B (zh)
AU (1) AU2008291833B2 (zh)
CA (3) CA2844647C (zh)
CY (1) CY1119031T1 (zh)
DK (2) DK2865755T3 (zh)
ES (2) ES2534435T3 (zh)
HK (2) HK1138326A1 (zh)
HR (2) HRP20150328T1 (zh)
LT (1) LT2865755T (zh)
MX (1) MX2009010411A (zh)
NZ (1) NZ580487A (zh)
PL (2) PL2865755T3 (zh)
PT (2) PT2865755T (zh)
SG (2) SG10201507969PA (zh)
SI (2) SI2865755T1 (zh)
WO (1) WO2009027830A2 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005276145C1 (en) 2004-08-26 2011-01-06 Engeneic Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
PL2865755T3 (pl) * 2007-03-30 2017-08-31 Engeneic Molecular Delivery Pty Ltd Nienaruszone komórki pochodzenia bakteryjnego, obejmujące regulatorowy RNA
DE102009017908A1 (de) * 2009-04-17 2010-10-21 Kist-Europe Forschungsgesellschaft Mbh Vektor für den Transport von mikrobiologischen Organismen zu Krankheitsherden
WO2011034421A1 (en) * 2009-09-16 2011-03-24 Stichting Het Nederlands Kanker Instituut Fra-1 target genes as drug targets for treating cancer
MX359410B (es) 2011-12-13 2018-09-27 Engeneic Molecular Delivery Pty Ltd Minicélulas intactas derivadas bacterialmente para suministro de agentes terapéuticos a tumores cerebrales.
US9006200B2 (en) 2013-03-13 2015-04-14 Asbestos Diseases Research Foundation MicroRNA-based approach to treating malignant pleural mesothelioma
JP6538031B2 (ja) 2013-10-04 2019-07-03 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 薬物を負荷した二重特異性リガンド標的化ミニ細胞およびインターフェロン−γを用いた併用腫瘍治療
AU2015326407C1 (en) * 2014-10-03 2021-06-24 Engeneic Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
AU2017339841A1 (en) 2016-10-06 2019-05-02 Engeneic Molecular Delivery Pty Ltd Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same
US11649265B2 (en) 2017-04-28 2023-05-16 Agrospheres, Inc. Compositions and methods for the encapsulation and scalable delivery of agrochemicals
WO2018201160A1 (en) 2017-04-28 2018-11-01 Agrospheres, Inc. Compositions and methods for enzyme immobilization
MX2020003074A (es) * 2017-09-25 2020-09-14 Agrospheres Inc Composiciones y metodos para la produccion y la administracion expansible de productos biologicos.
US11504402B2 (en) 2018-07-23 2022-11-22 Engenelc Molecular Delivery Pty Ltd Compositions comprising bacterially derived minicells and methods of using the same
WO2021133846A2 (en) * 2019-12-23 2021-07-01 Agrospheres, Inc. Compositions and methods for enhanced uptake of active ingredients for animal health and nutrition

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4496778A (en) 1983-10-03 1985-01-29 Exxon Research & Engineering Co. Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper Co-catalyst, and an aromatic amine based promoter
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
BR0010316A (pt) 1999-05-11 2004-04-27 Ortho Mcnell Pharmaceutical In Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente
US20050222057A1 (en) 2001-10-15 2005-10-06 Himanshu Brahmbhatt Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo
US20040053289A1 (en) * 2002-09-09 2004-03-18 The Regents Of The University Of California Short interfering nucleic acid hybrids and methods thereof
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
CA2549840C (en) 2003-12-09 2012-03-20 Engeneic Molecular Delivery Pty Ltd. Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
CN1925873B (zh) 2004-02-02 2011-02-09 恩杰内克分子递送有限公司 经细菌来源的完整微细胞在体外将药物靶向递送至哺乳动物细胞的组合物和方法
AU2005276145C1 (en) * 2004-08-26 2011-01-06 Engeneic Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
PL2865755T3 (pl) * 2007-03-30 2017-08-31 Engeneic Molecular Delivery Pty Ltd Nienaruszone komórki pochodzenia bakteryjnego, obejmujące regulatorowy RNA

Also Published As

Publication number Publication date
PL2145002T3 (pl) 2015-06-30
LT2865755T (lt) 2017-07-25
ES2534435T3 (es) 2015-04-22
PT2145002E (pt) 2015-04-29
CA2682704A1 (en) 2009-03-05
MX2009010411A (es) 2009-11-23
EP2145002A2 (en) 2010-01-20
EP2532746A2 (en) 2012-12-12
EP3205724B1 (en) 2019-05-08
EP2865755A2 (en) 2015-04-29
AU2008291833A1 (en) 2009-03-05
EP2865755B1 (en) 2017-02-01
CN101715489B (zh) 2016-05-25
SI2145002T1 (sl) 2015-05-29
SI2865755T1 (sl) 2017-06-30
SG10201507969PA (en) 2015-10-29
JP5167338B2 (ja) 2013-03-21
CN105854029A (zh) 2016-08-17
HRP20150328T1 (hr) 2015-05-22
AU2008291833B2 (en) 2012-11-08
EP2532746A3 (en) 2013-08-14
EP3205724A1 (en) 2017-08-16
CA2933978C (en) 2018-08-21
NZ580487A (en) 2012-04-27
SG10201804257RA (en) 2018-06-28
CA2682704C (en) 2014-07-08
DK2865755T3 (en) 2017-05-15
CA2933978A1 (en) 2009-03-05
EP2865755A3 (en) 2015-05-06
JP2010523487A (ja) 2010-07-15
PT2865755T (pt) 2017-05-26
CN105854029B (zh) 2019-10-18
EP2145002B1 (en) 2015-01-07
ES2626179T3 (es) 2017-07-24
WO2009027830A3 (en) 2009-05-14
EP3564372A1 (en) 2019-11-06
HRP20170662T1 (hr) 2017-07-14
CA2844647C (en) 2016-07-26
CY1119031T1 (el) 2018-01-10
WO2009027830A2 (en) 2009-03-05
DK2145002T3 (en) 2015-04-20
CN101715489A (zh) 2010-05-26
CA2844647A1 (en) 2009-03-05
PL2865755T3 (pl) 2017-08-31
HK1209786A1 (zh) 2016-04-08

Similar Documents

Publication Publication Date Title
HRP20150328T1 (hr) Bakterijski dobivene, intaktne mini-stanice koje obuhvaä†aju funkcionalnu nukleinsku kiselinu, bez plazmida, za in vivo dopremu do stanica sisavaca
HRP20180934T1 (hr) Optimizirani sustav unosa in vivo s endosomolitičkim sredstvima za konjugate nukleinskih kiselina
HK1221266A1 (zh) 單細胞中的基因表達分析
PT2386640E (pt) Distribuição de ácidos nucleicos funcionais a células de mamífero através de minicélulas intactas, bacterialmente derivadas
EP2320495A4 (en) INTERCONNECTING SYSTEM FOR BATTERY ELEMENTS
EP2352197A4 (en) FUEL CELL SYSTEM
EP2248214A4 (en) FUEL CELL SYSTEM
EP2237354A4 (en) FUEL CELL SYSTEM
PL2277222T3 (pl) Układ ogniw paliwowych
PL2274430T3 (pl) Komórki regenerujące nerwy ze zmianami w metylacji DNA
EP2169057A4 (en) DOUBLE STRANDED RNA FROM A LACTIC ACID BACTERIUM
GB2470874B (en) Fuel cell system
GB0800524D0 (en) Cell culture system
EP2251924A4 (en) FUEL CELL SYSTEM
EP2362909A4 (en) MAMMALIAN GENES INVOLVED IN INFECTION
EP2282370A4 (en) FUEL CELL SYSTEM
EP2220228A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE ADMINISTRATION OF NUCLEIC ACIDS IN CELLS
HK1142278A1 (en) Nucleic acid complex and nucleic acid delivery composition
HK1139041A1 (zh) 速效型核酸轉運用載體組合物
EP2421880A4 (en) COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY
GB0805487D0 (en) Efficient insertion of DNA into ES cells
GB0808778D0 (en) Cell culture technique